Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
EV-302
The efficacy of PADCEV in combination with pembrolizumab was evaluated in EV-302 (NCT04223856), an open label, randomized, multicenter trial that enrolled 886 patients with locally advanced or metastatic urothelial cancer who received no prior systemic therapy for locally advanced or metastatic disease. Patients with active CNS metastases, ongoing sensory or motor neuropathy Grade ≥2, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms were excluded.
Patients were randomized 1:1 to receive either:
Randomization was stratified by cisplatin eligibility, PD-L1 expression, and presence of liver metastases.
The median age was 69 years (range: 22 to 91); 77% were male; 67% were White, 22% were Asian, 1% were Black or African American, and 10% were unknown or other; 12% were Hispanic or Latino. Patients had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 (49%), 1 (47%) or 2 (3%). Forty-seven percent of patients had a documented baseline HbA1c of <5.7%. At baseline, 95% of patients had metastatic urothelial cancer, including 72% with visceral and 22% with liver metastases, and 5% had locally advanced urothelial cancer. Eighty-five percent of patients had urothelial carcinoma (UC) histology including 6% with UC mixed squamous differentiation and 2% with UC mixed other histologic variants. Forty-six percent of patients were considered cisplatin-ineligible and 54% were considered cisplatin-eligible at time of randomization.
The major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS) as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additional efficacy outcome measures included objective response rate (ORR) as assessed by BICR.
The trial demonstrated statistically significant improvements in OS, PFS, and ORR for patients randomized to PADCEV in combination with pembrolizumab as compared to platinum-based chemotherapy. Efficacy results were consistent across all stratified patient subgroups.
Table 14 and Figures 2-3 summarize the efficacy results for EV-302.
Endpoint | PADCEV with pembrolizumab n=442 | Cisplatin or carboplatin with gemcitabine n=444 |
---|---|---|
NE = Not estimable. | ||
| ||
Overall Survival | ||
Number (%) of patients with events | 133 (30.1) | 226 (50.9) |
Median in months (95% CI) | 31.5 (25.4, NE) | 16.1 (13.9, 18.3) |
Hazard ratio (95% CI)* | 0.47 (0.38, 0.58) | |
<0.0001 | ||
Progression Free Survival | ||
Number (%) of patients with events | 223 (50.5) | 307 (69.1) |
Median in months (95% CI) | 12.5 (10.4, 16.6) | 6.3 (6.2, 6.5) |
Hazard ratio (95% CI)* | 0.45 (0.38, 0.54) | |
<0.0001 | ||
Confirmed Objective Response Rate§ | ||
ORR (%) (95% CI) | 67.7 (63.1, 72.1) | 44.4 (39.7, 49.2) |
<0.0001 | ||
Complete response rate (%) | 29.1 | 12.5 |
Partial response rate (%) | 38.7 | 32.0 |
Cisplatin Ineligible Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
EV-103
The efficacy of PADCEV in combination with pembrolizumab was evaluated in EV-103 (NCT03288545), an open-label, multi-cohort (dose escalation cohort, Cohort A, Cohort K) trial in patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-containing chemotherapy and received no prior systemic therapy for locally advanced or metastatic disease. Patients with active CNS metastases, ongoing sensory or motor neuropathy Grade ≥2, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms were excluded from participating in the trial.
Patients in the dose escalation cohort (n=5), Cohort A (n=40), and Cohort K (n=76) received PADCEV 1.25 mg/kg as an IV infusion over 30 minutes on Days 1 and 8 of a 21-day cycle followed by pembrolizumab 200 mg as an IV infusion on Day 1 of a 21-day cycle approximately 30 minutes after PADCEV. Patients were treated until disease progression or unacceptable toxicity.
A total of 121 patients received PADCEV in combination with pembrolizumab. The median age was 71 years (range: 51 to 91); 74% were male; 85% were White, 5% were Black, 4% were Asian and 6% were other, unknown or not reported. Ten percent of patients were Hispanic or Latino. Forty-five percent of patients had an ECOG performance status of 1 and 15% had an ECOG performance status of 2. Forty-seven percent of patients had a documented baseline HbA1c of <5.7%. Reasons for cisplatin ineligibility included: 60% with baseline creatinine clearance of 30 ̶ 59 mL/min, 10% with ECOG PS of 2, 13% with Grade 2 or greater hearing loss, and 16% with more than one cisplatin-ineligibility criteria.
At baseline, 97.5% of patients had metastatic urothelial cancer and 2.5% of patients had locally advanced urothelial cancer. Thirty-seven percent of patients had upper tract disease. Eighty-four percent of patients had visceral metastasis at baseline including 22% with liver metastases. Thirty-nine percent of patients had transitional cell carcinoma (TCC) histology; 13% had TCC with squamous differentiation and 48% had TCC with other histologic variants.
The major efficacy outcome measures were ORR and DoR as assessed by BICR according to RECIST v1.1.
The median follow-up time for the dose escalation cohort + Cohort A was 44.7 months (range: 0.7 to 52.4) and for Cohort K was 14.8 months (range: 0.6 to 26.2).
Efficacy results are presented in Table 15 below.
PADCEV in combination with pembrolizumab n=121 | |
---|---|
Confirmed ORR (95% CI) | 68% (58.7, 76.0) |
| 12% |
| 55% |
The median duration of response for the dose escalation cohort + Cohort A was 22.1 months (range: 1.0+ to 46.3+) and for Cohort K was not reached (range: 1.2 to 24.1+).
Previously Treated Locally Advanced or Metastatic Urothelial Cancer
EV-301
The efficacy of PADCEV as a single agent was evaluated in EV-301 (NCT03474107), an open-label, randomized, multicenter trial that enrolled 608 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. Patients were randomized 1:1 to receive either PADCEV 1.25 mg/kg on Days 1, 8 and 15 of a 28-day cycle or investigator’s choice of chemotherapy. Randomization was stratified by ECOG PS (0 vs 1), region of world (Western Europe vs US vs Rest of World), and presence of liver metastasis.
Patients were excluded if they had active central nervous system (CNS) metastases, ongoing sensory or motor neuropathy ≥Grade 2, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms.
The median age was 68 years (range: 30 to 88 years) and 77% were male. Racial demographics were reported as White (52%), Asian (33%), Black (0.7%), Native Hawaiian or Other Pacific Islander (0.2%) or not reported (15%). Nine percent of patients were Hispanic or Latino. All patients had a baseline ECOG performance status of 0 (40%) or 1 (60%). Thirty-four percent of patients had tumors located in the upper tract that included the renal pelvis and ureter. Eighty percent of patients had visceral metastases including 31% with liver metastases. Seventy-six percent of patients had pure TCC histology; 14% had TCC with other histologic variants; and 10% had other tumor histologies including adenocarcinoma and squamous cell carcinoma. The median number of prior therapies was 2 (range 1 to ≥3). Sixty-three percent of patients received prior cisplatin-based regimens, 26% received prior carboplatin-based regimens, and an additional 11% received both cisplatin and carboplatin-based regimens. Patients on the control arm received docetaxel (38%), paclitaxel (36%) or vinflunine (25%).
The major efficacy outcome measures were OS, PFS, and ORR assessed by investigator using RECIST v1.1. Efficacy results were consistent across all stratified patient subgroups.
Table 16 and Figures 4-5 summarize the efficacy results for EV-301.
Endpoint | PADCEV n=301 | Chemotherapy n=307 |
---|---|---|
Overall Survival* | ||
Number (%) of patients with events | 134 (44.5) | 167 (54.4) |
Median in months (95% CI) | 12.9 (10.6, 15.2) | 9.0 (8.1, 10.7) |
Hazard ratio (95% CI) | 0.70 (0.56, 0.89) | |
p-value | 0.0014 | |
Progression Free Survival* | ||
Number (%) of patients with events | 201 (66.8) | 231 (75.2) |
Median in months (95% CI) | 5.6 (5.3, 5.8) | 3.7 (3.5, 3.9) |
Hazard ratio (95% CI) | 0.62 (0.51, 0.75) | |
p-value | <0.0001 | |
Overall Response Rate (CR + PR)† | ||
ORR (%) (95% CI) | 40.6 (34.9, 46.5) | 17.9 (13.7, 22.8) |
p-value | <0.0001 | |
Complete response rate (%) | 4.9 | 2.7 |
Partial response rate (%) | 35.8 | 15.2 |
EV-201, Cohort 1
The efficacy of PADCEV as a single agent was also investigated in Cohort 1 of EV-201 (NCT03219333), a single-arm, multi-cohort, multicenter trial that enrolled 125 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy. Patients were excluded if they had active central nervous system (CNS) metastases, ongoing sensory or motor neuropathy ≥Grade 2, heart failure, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms.
PADCEV was administered at a dose of 1.25 mg/kg, as an intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
The median age was 69 years (range: 40 to 84 years) and 70% were male. Racial demographics were reported as White (85%), Asian (9%), Black (2%), Other (0.8%) or not reported (4%). Four percent of patients were Hispanic or Latino. All patients had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 (32%) or 1 (68%). Ninety percent of patients had visceral metastases including 40% with liver metastases. Approximately two-thirds (67%) of patients had pure transitional cell carcinoma (TCC) histology; 33% had TCC with other histologic variants. The median number of prior systemic therapies was 3 (range: 1 to 6). Sixty-six percent of patients received prior cisplatin-based regimens, 26% received prior carboplatin-based regimens, and an additional 8% received both cisplatin and carboplatin-based regimens.
The major efficacy outcome measures were confirmed objective response rate (ORR) and duration of response (DOR) assessed by BICR using RECIST v1.1.
Efficacy results are presented in Table 17.
Endpoint | PADCEV n=125 |
---|---|
NE = not estimable | |
| |
Confirmed ORR (95% CI) | 44% (35.1, 53.2) |
Complete Response Rate (CR) | 12% |
Partial Response Rate (PR) | 32% |
Median* Duration of Response, months (95% CI) | 7.6 (6.3, NE) |
Previously Treated Cisplatin Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer
EV-201, Cohort 2
The efficacy of PADCEV as a single agent was also evaluated in Cohort 2 of EV-201, a single-arm, multi-cohort, multicenter trial in 89 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and were cisplatin ineligible and did not receive platinum in the locally advanced or metastatic setting. Patients were excluded if they had active CNS metastases, ongoing sensory or motor neuropathy ≥Grade 2, heart failure, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms.
PADCEV was administered at a dose of 1.25 mg/kg, as an intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
The median age was 75 years (range: 49 to 90 years), 74% were male. Racial demographics were reported as White (70%), Asian (22%) or not reported (8%). One percent of patients were Hispanic or Latino. Patients had a baseline ECOG performance status of 0 (42%), 1 (46%) and 2 (12%). Forty-three percent of patients had tumors located in the upper tract that included the renal pelvis and ureter. Seventy-nine percent of patients had visceral metastases and 24% had liver metastases.
Reasons for cisplatin ineligibility included: 66% with baseline creatinine clearance of 30 – 59 mL/min, 7% with ECOG PS of 2, 15% with Grade 2 or greater hearing loss, and 12% with more than one cisplatin-ineligibility criteria. Seventy percent of patients had TCC histology; 13% had TCC with squamous differentiation and 17% had TCC with other histologic variants.
The median number of prior systemic therapies was 1 (range: 1 to 4).
Efficacy results are presented in Table 18 below.
NE = not estimable | |
| |
Endpoint | PADCEV n=89 |
Confirmed ORR (95% CI) | 51% (39.8, 61.3) |
Complete Response Rate (CR) | 22% |
Partial Response Rate (PR) | 28% |
Median* Duration of Response, months (95% CI) | 13.8 (6.4, NE) |
Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
EV-302
The efficacy of PADCEV in combination with pembrolizumab was evaluated in EV-302 (NCT04223856), an open label, randomized, multicenter trial that enrolled 886 patients with locally advanced or metastatic urothelial cancer who received no prior systemic therapy for locally advanced or metastatic disease. Patients with active CNS metastases, ongoing sensory or motor neuropathy Grade ≥2, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms were excluded.
Patients were randomized 1:1 to receive either:
Randomization was stratified by cisplatin eligibility, PD-L1 expression, and presence of liver metastases.
The median age was 69 years (range: 22 to 91); 77% were male; 67% were White, 22% were Asian, 1% were Black or African American, and 10% were unknown or other; 12% were Hispanic or Latino. Patients had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 (49%), 1 (47%) or 2 (3%). Forty-seven percent of patients had a documented baseline HbA1c of <5.7%. At baseline, 95% of patients had metastatic urothelial cancer, including 72% with visceral and 22% with liver metastases, and 5% had locally advanced urothelial cancer. Eighty-five percent of patients had urothelial carcinoma (UC) histology including 6% with UC mixed squamous differentiation and 2% with UC mixed other histologic variants. Forty-six percent of patients were considered cisplatin-ineligible and 54% were considered cisplatin-eligible at time of randomization.
The major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS) as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additional efficacy outcome measures included objective response rate (ORR) as assessed by BICR.
The trial demonstrated statistically significant improvements in OS, PFS, and ORR for patients randomized to PADCEV in combination with pembrolizumab as compared to platinum-based chemotherapy. Efficacy results were consistent across all stratified patient subgroups.
Table 14 and Figures 2-3 summarize the efficacy results for EV-302.
Endpoint | PADCEV with pembrolizumab n=442 | Cisplatin or carboplatin with gemcitabine n=444 |
---|---|---|
NE = Not estimable. | ||
| ||
Overall Survival | ||
Number (%) of patients with events | 133 (30.1) | 226 (50.9) |
Median in months (95% CI) | 31.5 (25.4, NE) | 16.1 (13.9, 18.3) |
Hazard ratio (95% CI)* | 0.47 (0.38, 0.58) | |
<0.0001 | ||
Progression Free Survival | ||
Number (%) of patients with events | 223 (50.5) | 307 (69.1) |
Median in months (95% CI) | 12.5 (10.4, 16.6) | 6.3 (6.2, 6.5) |
Hazard ratio (95% CI)* | 0.45 (0.38, 0.54) | |
<0.0001 | ||
Confirmed Objective Response Rate§ | ||
ORR (%) (95% CI) | 67.7 (63.1, 72.1) | 44.4 (39.7, 49.2) |
<0.0001 | ||
Complete response rate (%) | 29.1 | 12.5 |
Partial response rate (%) | 38.7 | 32.0 |
Cisplatin Ineligible Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
EV-103
The efficacy of PADCEV in combination with pembrolizumab was evaluated in EV-103 (NCT03288545), an open-label, multi-cohort (dose escalation cohort, Cohort A, Cohort K) trial in patients with locally advanced or metastatic urothelial cancer who were ineligible for cisplatin-containing chemotherapy and received no prior systemic therapy for locally advanced or metastatic disease. Patients with active CNS metastases, ongoing sensory or motor neuropathy Grade ≥2, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms were excluded from participating in the trial.
Patients in the dose escalation cohort (n=5), Cohort A (n=40), and Cohort K (n=76) received PADCEV 1.25 mg/kg as an IV infusion over 30 minutes on Days 1 and 8 of a 21-day cycle followed by pembrolizumab 200 mg as an IV infusion on Day 1 of a 21-day cycle approximately 30 minutes after PADCEV. Patients were treated until disease progression or unacceptable toxicity.
A total of 121 patients received PADCEV in combination with pembrolizumab. The median age was 71 years (range: 51 to 91); 74% were male; 85% were White, 5% were Black, 4% were Asian and 6% were other, unknown or not reported. Ten percent of patients were Hispanic or Latino. Forty-five percent of patients had an ECOG performance status of 1 and 15% had an ECOG performance status of 2. Forty-seven percent of patients had a documented baseline HbA1c of <5.7%. Reasons for cisplatin ineligibility included: 60% with baseline creatinine clearance of 30 ̶ 59 mL/min, 10% with ECOG PS of 2, 13% with Grade 2 or greater hearing loss, and 16% with more than one cisplatin-ineligibility criteria.
At baseline, 97.5% of patients had metastatic urothelial cancer and 2.5% of patients had locally advanced urothelial cancer. Thirty-seven percent of patients had upper tract disease. Eighty-four percent of patients had visceral metastasis at baseline including 22% with liver metastases. Thirty-nine percent of patients had transitional cell carcinoma (TCC) histology; 13% had TCC with squamous differentiation and 48% had TCC with other histologic variants.
The major efficacy outcome measures were ORR and DoR as assessed by BICR according to RECIST v1.1.
The median follow-up time for the dose escalation cohort + Cohort A was 44.7 months (range: 0.7 to 52.4) and for Cohort K was 14.8 months (range: 0.6 to 26.2).
Efficacy results are presented in Table 15 below.
PADCEV in combination with pembrolizumab n=121 | |
---|---|
Confirmed ORR (95% CI) | 68% (58.7, 76.0) |
| 12% |
| 55% |
The median duration of response for the dose escalation cohort + Cohort A was 22.1 months (range: 1.0+ to 46.3+) and for Cohort K was not reached (range: 1.2 to 24.1+).
Previously Treated Locally Advanced or Metastatic Urothelial Cancer
EV-301
The efficacy of PADCEV as a single agent was evaluated in EV-301 (NCT03474107), an open-label, randomized, multicenter trial that enrolled 608 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy. Patients were randomized 1:1 to receive either PADCEV 1.25 mg/kg on Days 1, 8 and 15 of a 28-day cycle or investigator’s choice of chemotherapy. Randomization was stratified by ECOG PS (0 vs 1), region of world (Western Europe vs US vs Rest of World), and presence of liver metastasis.
Patients were excluded if they had active central nervous system (CNS) metastases, ongoing sensory or motor neuropathy ≥Grade 2, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms.
The median age was 68 years (range: 30 to 88 years) and 77% were male. Racial demographics were reported as White (52%), Asian (33%), Black (0.7%), Native Hawaiian or Other Pacific Islander (0.2%) or not reported (15%). Nine percent of patients were Hispanic or Latino. All patients had a baseline ECOG performance status of 0 (40%) or 1 (60%). Thirty-four percent of patients had tumors located in the upper tract that included the renal pelvis and ureter. Eighty percent of patients had visceral metastases including 31% with liver metastases. Seventy-six percent of patients had pure TCC histology; 14% had TCC with other histologic variants; and 10% had other tumor histologies including adenocarcinoma and squamous cell carcinoma. The median number of prior therapies was 2 (range 1 to ≥3). Sixty-three percent of patients received prior cisplatin-based regimens, 26% received prior carboplatin-based regimens, and an additional 11% received both cisplatin and carboplatin-based regimens. Patients on the control arm received docetaxel (38%), paclitaxel (36%) or vinflunine (25%).
The major efficacy outcome measures were OS, PFS, and ORR assessed by investigator using RECIST v1.1. Efficacy results were consistent across all stratified patient subgroups.
Table 16 and Figures 4-5 summarize the efficacy results for EV-301.
Endpoint | PADCEV n=301 | Chemotherapy n=307 |
---|---|---|
Overall Survival* | ||
Number (%) of patients with events | 134 (44.5) | 167 (54.4) |
Median in months (95% CI) | 12.9 (10.6, 15.2) | 9.0 (8.1, 10.7) |
Hazard ratio (95% CI) | 0.70 (0.56, 0.89) | |
p-value | 0.0014 | |
Progression Free Survival* | ||
Number (%) of patients with events | 201 (66.8) | 231 (75.2) |
Median in months (95% CI) | 5.6 (5.3, 5.8) | 3.7 (3.5, 3.9) |
Hazard ratio (95% CI) | 0.62 (0.51, 0.75) | |
p-value | <0.0001 | |
Overall Response Rate (CR + PR)† | ||
ORR (%) (95% CI) | 40.6 (34.9, 46.5) | 17.9 (13.7, 22.8) |
p-value | <0.0001 | |
Complete response rate (%) | 4.9 | 2.7 |
Partial response rate (%) | 35.8 | 15.2 |
EV-201, Cohort 1
The efficacy of PADCEV as a single agent was also investigated in Cohort 1 of EV-201 (NCT03219333), a single-arm, multi-cohort, multicenter trial that enrolled 125 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy. Patients were excluded if they had active central nervous system (CNS) metastases, ongoing sensory or motor neuropathy ≥Grade 2, heart failure, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms.
PADCEV was administered at a dose of 1.25 mg/kg, as an intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
The median age was 69 years (range: 40 to 84 years) and 70% were male. Racial demographics were reported as White (85%), Asian (9%), Black (2%), Other (0.8%) or not reported (4%). Four percent of patients were Hispanic or Latino. All patients had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 (32%) or 1 (68%). Ninety percent of patients had visceral metastases including 40% with liver metastases. Approximately two-thirds (67%) of patients had pure transitional cell carcinoma (TCC) histology; 33% had TCC with other histologic variants. The median number of prior systemic therapies was 3 (range: 1 to 6). Sixty-six percent of patients received prior cisplatin-based regimens, 26% received prior carboplatin-based regimens, and an additional 8% received both cisplatin and carboplatin-based regimens.
The major efficacy outcome measures were confirmed objective response rate (ORR) and duration of response (DOR) assessed by BICR using RECIST v1.1.
Efficacy results are presented in Table 17.
Endpoint | PADCEV n=125 |
---|---|
NE = not estimable | |
| |
Confirmed ORR (95% CI) | 44% (35.1, 53.2) |
Complete Response Rate (CR) | 12% |
Partial Response Rate (PR) | 32% |
Median* Duration of Response, months (95% CI) | 7.6 (6.3, NE) |
Previously Treated Cisplatin Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer
EV-201, Cohort 2
The efficacy of PADCEV as a single agent was also evaluated in Cohort 2 of EV-201, a single-arm, multi-cohort, multicenter trial in 89 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and were cisplatin ineligible and did not receive platinum in the locally advanced or metastatic setting. Patients were excluded if they had active CNS metastases, ongoing sensory or motor neuropathy ≥Grade 2, heart failure, or uncontrolled diabetes defined as hemoglobin A1C (HbA1c) ≥8% or HbA1c ≥7% with associated diabetes symptoms.
PADCEV was administered at a dose of 1.25 mg/kg, as an intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
The median age was 75 years (range: 49 to 90 years), 74% were male. Racial demographics were reported as White (70%), Asian (22%) or not reported (8%). One percent of patients were Hispanic or Latino. Patients had a baseline ECOG performance status of 0 (42%), 1 (46%) and 2 (12%). Forty-three percent of patients had tumors located in the upper tract that included the renal pelvis and ureter. Seventy-nine percent of patients had visceral metastases and 24% had liver metastases.
Reasons for cisplatin ineligibility included: 66% with baseline creatinine clearance of 30 – 59 mL/min, 7% with ECOG PS of 2, 15% with Grade 2 or greater hearing loss, and 12% with more than one cisplatin-ineligibility criteria. Seventy percent of patients had TCC histology; 13% had TCC with squamous differentiation and 17% had TCC with other histologic variants.
The median number of prior systemic therapies was 1 (range: 1 to 4).
Efficacy results are presented in Table 18 below.
NE = not estimable | |
| |
Endpoint | PADCEV n=89 |
Confirmed ORR (95% CI) | 51% (39.8, 61.3) |
Complete Response Rate (CR) | 22% |
Partial Response Rate (PR) | 28% |
Median* Duration of Response, months (95% CI) | 13.8 (6.4, NE) |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.